Shots:
- The P-IIb PAGANINI study involves assessing the efficacy, safety & tolerability of eliapixant (25, 75 or 150mg, bid) vs PBO in 310 patients with RCC for 12wks. and it lasted for 18wks. in total
- The study met its 1EPs i.e. reduction in the 24hrs. cough count of up to 27% with 75mg dose and showed a positive benefit-risk profile with mild to moderate AEs. The results of the PAGANINI study were presented at the virtual ERS International Congress 2021
- Eliapixant (BAY1817080, PO) is an investigational potent and selective P2X3 receptor antagonist
Click here to read the full press release/ article | Ref: Bayer | Image: Bayer
The post Bayer Reports Results of Eliapixant in P-IIb PAGANINI Study for Patients with Refractory Chronic Cough first appeared on PharmaShots.
